Johnson &amp; Johnson (JNJ.US) announced on Monday that it will acquire the private company Halda Therapeutics for $3.05 billion in cash, thereby expanding its business in the field of solid tumors and prostate cancer treatment.
Halda's leading candidate drug HLD-0915 is currently in the early to mid-stage development for the treatment of prostate cancer, and the company also has several early experimental therapies targeting breast cancer, lung cancer, and other types of tumors. Johnson &amp; Johnson expects the transaction to be completed in the coming months

Johnson & Johnson announced on Monday that it will acquire the private company Halda Therapeutics for $3.05 billion in cash, thereby expanding its business in the field of solid tumors and prostate cancer treatment. Halda's leading candidate drug HLD-0915 is currently in the early to mid-stage development for the treatment of prostate cancer, and the company also has several early experimental therapies targeting breast cancer, lung cancer, and other types of tumors. Johnson & Johnson expects the transaction to be completed in the coming months

Johnson & Johnson plans to acquire a cancer therapy research company for over $3 billion